Skip to main content

Advertisement

Log in

Epstein–Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time?

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

The frequency and clinical features of Epstein–Barr virus (EBV)-associated primary central nervous system lymphoma (PCNSL) in elderly patients were investigated in this study. Thirty-three PCNSL cases were enrolled in the retrospective study. Biopsies were performed, and tissue was embedded in paraffin and sectioned. In-situ hybridization of EBV-encoded small RNAs was then conducted. Specimens were scored as having one of three possible results: negative (no EBV-positive cells), slightly positive (<50% EBV-positive cells), and strongly positive (>50% EBV-positive cells). Fifteen cases were negative for EBV expression. Sixteen cases were slightly positive, and two cases (68 and 79 years of age) were strongly positive. The incidence of strongly positive EBV expression in PCNSL was 6.1%. The incidence of strongly positive EBV expression in PCNSL patients ≥65 years of age was 13%. Median survival time differed significantly among PCNSL patients treated with high-dose methotrexate and radiotherapy. Importantly, the strongly EBV-positive PCNSL cases had the worst outcomes, and the EBV-negative PCNSL cases had the best outcomes. These results suggest that EBV infection may affect the treatment outcome of PCNSL. In the future, examination of EBV expression in PCNSL patients who receive individualized treatment may be useful.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Committee of Brain Tumor Registry of Japan (2003) Report of brain tumor registry of Japan (1984–2000) Part I General features of brain tumors. Neurol Med Chir (Tokyo) 49 Suppl:S1–S25

  2. Oyama T, Ichimura K, Suzuki R et al (2003) Senile EBV + B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26

    Article  PubMed  Google Scholar 

  3. Kleinschmidt-DeMasters BK, Damek DM, Lillehei KO et al (2008) Epstein Barr virus-associated primary CNS lymphomas in elderly patients on immunosuppressive medications. J Neuropathol Exp Neurol 67:1103–1111

    Article  PubMed  CAS  Google Scholar 

  4. Hsiao SC, Ichinohasama R, Lin S et al (2009) EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate. Pathol Res Pract 205:43–49

    Article  PubMed  Google Scholar 

  5. Sierra del Rio M, Rousseau A, Soussain C et al (2009) Primary CNS lymphoma in immunocompetent patients. Oncologist 14:526–539

    Article  PubMed  CAS  Google Scholar 

  6. Oyama T, Yamamoto K, Asano N et al (2007) Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 13:5124–5132

    Article  PubMed  CAS  Google Scholar 

  7. Gibson SE, His ED (2009) Epstein–Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 40:653–661

    Article  PubMed  Google Scholar 

  8. Kuze T, Nakamura N, Hashimoto Y et al (2000) The characteristic of Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV+ and EBV− cases in Japanese population. Jpn J Cancer Res 91:1233–1240

    PubMed  CAS  Google Scholar 

  9. Park S, Lee J, Ko YH et al (2007) The impact of Epstein–Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 110:972–978

    Article  PubMed  CAS  Google Scholar 

  10. Yoshino T, Nakamura S, Matsuno Y et al (2006) Epstein–Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma. Cancer Sci 97:163–166

    Article  PubMed  CAS  Google Scholar 

  11. Kitai R, Matsuda K, Adachi E et al (2010) Epstein–Barr virus-associated primary central nervous system lymphoma in the Japanese population. Neurol Med Chir (Tokyo) 50:114–118

    Article  Google Scholar 

  12. Sugita Y, Terasaki M, Niino D et al (2010) Epstein–Barr virus-associated primary central nervous system lymphomas in immunocompetent elderly patients: analysis for latent membrane protein-1 oncogene deletion and EBNA-2 strain typing. J Neurooncol 100:271–279

    Article  PubMed  CAS  Google Scholar 

  13. Ouyang Q, Wagner WM et al (2003) An age-related increase in the number of CD8+ T-cells carrying receptors for an immunodominant Epstein–Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev 124:477–485

    Article  PubMed  CAS  Google Scholar 

  14. Fagnoni FF, Vescovini R, Passeri G et al (2000) Shortage of circulating naïve CD8+ T cells provides new insights on immunodeficiency in aging. Blood 95:2860–2868

    PubMed  CAS  Google Scholar 

  15. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein–Barr virus and the origins of associated lymphomas. N Engl J Med 350:1328–1337

    Article  PubMed  CAS  Google Scholar 

  16. Morales D, Beltran B, De Mendoza FH et al (2010) Epstein–Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma 51:66–72

    Article  PubMed  CAS  Google Scholar 

  17. Clybouw C, McHichi B, Mouhamad S et al (2005) EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J Immunol 175:2968–2973

    PubMed  CAS  Google Scholar 

  18. Snow AL, Lambert SL, Natkunam Y et al (2006) EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol 177:3283–3293

    PubMed  CAS  Google Scholar 

  19. Roychowdhury S, Peng R, Baiocchi RA et al (2003) Experimental treatment of Epstein–Barr virus-associated primary central nervous system lymphoma. Cancer Res 63:965–971

    PubMed  CAS  Google Scholar 

  20. Soussain C, Muldoon LL, Varallyay C et al (2007) Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma. Clin Cancer Res 13:2504–2511

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satoshi Utsuki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Utsuki, S., Oka, H., Miyajima, Y. et al. Epstein–Barr virus (EBV)-associated primary central nervous system lymphoma: is incidence of EBV expression associated with median survival time?. Brain Tumor Pathol 28, 145–149 (2011). https://doi.org/10.1007/s10014-011-0020-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-011-0020-x

Keywords

Navigation